Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (368,445)	$ (198,382)	$ (191,490)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and accretion	13,276	18,575	14,057
Stock-based compensation expense	8,725	48,622	45,186
Loss on extinguishment of debt	1,049
Loss on purchase commitments	66,167
Write-off of Inventory	36,104
Loss on sale, abandonment/disposal or impairment of property and equipment	140,582	97	817
Interest incurred through borrowings under Sanofi Loan Facility	1,652
Write-off of derivative liability		(363)
Foreign exchange loss	2,697	(10)	2
Changes in assets and liabilities:
Inventory	(26,434)	(9,670)
Receivables from collaboration	50,413	(50,436)
Prepaid expenses and other current assets	13,485	(14,734)	(499)
Deferred product costs from collaboration	(13,539)
Other assets	150	(615)
Accounts payable	8,413	3,622	(1,071)
Accrued expenses and other current liabilities	(12,467)	2,276	3,675
Deferred product sales from collaboration	17,067
Deferred payments from collaboration	950	200,436
Other liabilities	2,927	2,915	591
Net cash (used in) provided by operating activities	(57,232)	4,086	(128,732)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(10,285)	(24,097)	(7,987)
Proceeds from sale of property and equipment	82
Net cash used in investing activities	(10,203)	(24,097)	(7,987)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock	4,146	12,341	3,534
Exercise of warrants for common stock	10,123	27,779	94,147
Proceeds from issuance of facility financing obligation & milestone rights		40,000	119,500
Facility financing obligation & milestone rights issuance costs			(598)
Milestone payment	(4,219)	(3,150)
Proceeds from issuance of common stock pursuant to at-the-market issuance	28,392		49,990
Issuance costs associated with the Tel Aviv Stock Exchange	(548)		(1,103)
Other	40
Payment of employment taxes related to vested restricted stock units	(1,858)	(26,908)	(4,801)
Net cash provided by financing activities	5,668	70,062	145,669
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(61,767)	50,051	8,950
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	120,841	70,790	61,840
CASH AND CASH EQUIVALENTS, END OF PERIOD	59,074	120,841	70,790
SUPPLEMENTAL CASH FLOWS DISCLOSURES:
Interest paid in cash, net of amounts capitalized to Construction in progress	13,355	11,218	13,452
Payment of 2015 notes and interest through issuance of common stock	8,253
Issuance of common stock pursuant to debt conversion by Deerfield		93,500	6,500
Non-cash construction in progress and property and equipment		1,768	856
Capitalization of interest on note payable to principal stockholder			7,886
Reduction of principal on note payable to principal stockholder upon issuance of common stock and exercise of warrants			78,000
Reclassification of deferred payments from collaboration to Sanofi loan facility and loss share obligation	59,337	3,034
TEL AVIV STOCK EXCHANGE
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock	36,142
Issuance costs associated with the Tel Aviv Stock Exchange	(1,432)
2015 Notes
CASH FLOWS FROM FINANCING ACTIVITIES:
Payment of 2015 notes	(64,287)
2018 Notes
CASH FLOWS FROM FINANCING ACTIVITIES:
Facility financing obligation & milestone rights issuance costs	$ (831)
2013 Notes
CASH FLOWS FROM FINANCING ACTIVITIES:
Payment of 2015 notes			$ (115,000)
Less portion of commitment asset
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Write-off Tranche B Commitment Asset		1,753
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of facility financing obligation & milestone rights		$ 20,000